Briciclib Sodium

N/A

Report date: 2024/04/09 10:15:24
NME

Base Information

Drug NameBriciclib Sodium
Drug Alias Name布利西利Briciclibum布瑞西利ON-014185 (free acid)ON-013105
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin D1 inhibitorsEukaryotic translation initiation factor 4E inhibitorsApoptosis inducers
TargetsEukaryotic translation initiation factor 4ECyclin D1
Therapy Area/IndicationsSolid tumoursLymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTemple University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTraws Pharma Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG